Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
G. Rajeev-Kumar, Sean P. Pitroda
Neoplasia (2022) Vol. 36, pp. 100867-100867
Open Access | Times Cited: 20

Showing 20 citing articles:

Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease
Irma Telarović, Carmen S. Yong, Lisa Kurz, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Nanotechnology‐Empowered Combination Cancer Immunotherapies: Mechanisms, Synergies, and Perspectives
Yuqing Pan, Xiangdong Xue, Xing‐Jie Liang
Advanced NanoBiomed Research (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 6
Oligometastatic Squamous Cell Carcinoma Treated With and Without Involved Site Radiation
Allen M. Chen
Oral Oncology Reports (2025), pp. 100707-100707
Open Access
Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation
Seung Young Lee, Joanna Pagacz, Sera Averbek, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 391-391
Open Access
Re-irradiation with Concurrent Pembrolizumab for Local-Regionally Recurrent Squamous Cell Carcinoma of the Head and Neck
Allen M. Chen, Jeremy P. Harris, Rupali Nabar, et al.
Oral Oncology Reports (2025), pp. 100714-100714
Open Access
Cost-Effectiveness of Pembrolizumab With Chemoradiotherapy for Locally Advanced Cervical Cancer
P. Travis Courtney, Puja Venkat, Ya‐Chen Tina Shih, et al.
JAMA Network Open (2025) Vol. 8, Iss. 3, pp. e250033-e250033
Open Access
Kaplan lecture 2023: lymphopenia in particle therapy
Marco Durante
International Journal of Radiation Biology (2024) Vol. 100, Iss. 5, pp. 669-677
Open Access | Times Cited: 3
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
Roberta Fazio, Alessandro Audisio, Valentina Daprà, et al.
Cancer Treatment Reviews (2024) Vol. 128, pp. 102752-102752
Closed Access | Times Cited: 3
A Mathematical Model for Predicting Patient Responses to Combined Radiotherapy with CTLA-4 Immune Checkpoint Inhibitors
Yongjin Kim, Bo‐Young Choe, Tae Suk Suh, et al.
Cells (2023) Vol. 12, Iss. 9, pp. 1305-1305
Open Access | Times Cited: 8
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
William Echavidre, Daniel Fagret, Marc Faraggi, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4839-4839
Open Access | Times Cited: 8
Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
Xiao‐Han Zhao, Hongmei Gao, Jingyuan Wen, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Genome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy
Nipun Verma, Paul Renauer, Chuanpeng Dong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
PD-L1 Expression in Paired Samples of Rectal Cancer
Mina Coussement, Roberta Fazio, Alessandro Audisio, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2606-2606
Open Access
Timing anti-PD-L1 checkpoint blockade immunotherapy to enhance tumor irradiation
Seung Young Lee, Joanna Pagacz, Sera Averbek, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies
Shivani Srivastava, Anuradha Tyagi, Vishakha Anand Pawar, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 413-433
Open Access
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma
Omar Elghawy, Adam Barsouk, Reema Patel, et al.
Immunotherapy (2024) Vol. 16, Iss. 16-17, pp. 1069-1078
Closed Access
Comparing Cisplatin Dosing Schedules in Concurrent Chemoradiotherapy for Locally Advanced Head-and-Neck Cancer: A Comprehensive Review of Weekly Versus 3-Weekly Regimens
Oscar Chi-Yu Yang, Nai-Wen Su, Yi‐Shing Leu, et al.
Journal of Cancer Research and Practice (2024) Vol. 11, Iss. 4, pp. 125-133
Open Access
Immune modulation during anti-cancer radio(immuno)therapy
Teresa Irianto, Udo S. Gaipl, Michael Rückert
International review of cell and molecular biology (2023), pp. 239-277
Closed Access | Times Cited: 1
Immune checkpoint inhibitors combined with radiotherapy/chemoradiotherapy in treating locally advanced or recurrent/metastatic esophageal squamous cell carcinoma: A real-world study
Xiao‐Han Zhao, Hongmei Gao, Jingyuan Wen, et al.
Research Square (Research Square) (2023)
Open Access
Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer
Lahcene Belaidi, Pascal Wang, K. Quintin, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5127-5127
Open Access
Page 1

Scroll to top